GMAB
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Genmab A/S
- Nom
- Genmab A/S
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $27.0B
- Employés
- 3,119
- PDG
- Jan van de Winkel
- Site web
- https://www.genmab.com
- Marché
- ADCTALXOBNTXCGENEXELINCY
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- —
- Last synced
-
2026-10-06 10:56:08
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
No Form 4 filings for this company in this window.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2025-01-16 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2024-12-16 | Josh S. Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2024-07-19 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2024-06-18 | Josh S. Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2023-10-16 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2023-09-15 | Josh S. Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2023-07-20 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2023-07-19 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2023-07-10 | Daniel Goldman | Sale (Full) | $50,001 - $100,000 |
| 2023-03-31 | Daniel Goldman | Sale (Partial) | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
GMAB presents a strong clinical catalyst with high-confidence Phase 3 EPCORE DLBCL-2 results and supportive Phase 2 Rina-S data, driving meaningful near-term momentum.
The first sentence of the analysis written for GMAB on 2026-10-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. No open-market purchase or sale value stored
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 2.02 · operating margin 34%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 91.7% | 95.4% | 98.6% | 100.0% | 100.0% | |
| Ebit Margin | 34.0% | 43.1% | 34.6% | 48.0% | 46.7% | |
| Ebitda Margin | 35.9% | 45.0% | 36.1% | 50.6% | 49.7% | |
| Operating Profit Margin | 33.6% | 31.1% | 32.3% | 43.2% | 35.1% | |
| Pretax Profit Margin | 32.4% | 42.6% | 34.2% | 47.9% | 46.5% | |
| Continuous Operations Profit Margin | 25.9% | 36.4% | 26.4% | 37.6% | 35.1% | |
| Net Profit Margin | 25.9% | 36.4% | 26.4% | 37.6% | 35.1% | |
| Bottom Line Profit Margin | 25.9% | 36.4% | 26.4% | 37.6% | 35.1% | |
| Current Ratio | 2.022 | 5.248 | 13.341 | 15.479 | 14.500 | |
| Quick Ratio | 2.009 | 5.236 | 13.318 | 15.479 | 14.500 | |
| Solvency Ratio | 0.148 | 0.906 | 1.248 | 2.049 | 1.319 | |
| Cash Ratio | 1.202 | 1.857 | 5.985 | 5.427 | 5.712 | |
| Price To Earnings Ratio | 19.910 | 12.387 | 32.564 | 35.292 | 57.215 | |
| Price To Earnings Growth Ratio | -0.228 | 0.148 | -1.563 | 0.418 | -1.502 | |
| Forward Price To Earnings Growth Ratio | -0.228 | 0.148 | -1.563 | 0.418 | -1.502 | |
| Price To Earnings Diluted Ratio | 20.039 | 12.387 | 32.564 | 35.634 | 57.726 | |
| Price To Earnings Diluted Growth Ratio | -0.229 | 0.148 | -1.622 | 0.422 | -1.521 | |
| Price To Book Ratio | 3.281 | 2.648 | 4.483 | 7.054 | 7.620 | |
| Price To Sales Ratio | 5.142 | 4.514 | 8.602 | 13.268 | 20.093 | |
| Price To Free Cash Flow Ratio | 16.647 | 12.811 | 20.232 | 53.535 | 85.589 | |
| Price To Operating Cash Flow Ratio | 16.128 | 12.503 | 19.202 | 49.197 | 75.908 | |
| Debt To Assets Ratio | 0.422 | 0.022 | 0.022 | 0.020 | 0.017 | |
| Debt To Equity Ratio | 0.930 | 0.028 | 0.024 | 0.022 | 0.019 | |
| Debt To Capital Ratio | 0.482 | 0.027 | 0.024 | 0.021 | 0.019 | |
| Long Term Debt To Capital Ratio | 0.462 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 2.202 | 1.248 | 1.116 | 1.104 | 1.110 | |
| Working Capital Turnover Ratio | 0.310 | 0.809 | 0.578 | 0.610 | 0.435 | |
| Operating Cash Flow Ratio | 0.834 | 1.464 | 2.971 | 2.146 | 1.421 | |
| Operating Cash Flow Sales Ratio | 0.319 | 0.361 | 0.448 | 0.270 | 0.265 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.969 | 0.976 | 0.949 | 0.919 | 0.887 | |
| Debt Service Coverage Ratio | 3.281 | 69.808 | 172.667 | 278.714 | 247.692 | |
| Interest Coverage Ratio | 20.492 | 55.858 | 197.074 | 298.429 | 227.154 | |
| Short Term Operating Cash Flow Coverage Ratio | 4.348 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.219 | 7.552 | 9.584 | 6.553 | 5.242 | |
| Capital Expenditure Coverage Ratio | 32.054 | 41.556 | 19.628 | 12.341 | 8.841 | |
| Dividend Paid And Capex Coverage Ratio | 32.054 | 41.556 | 19.628 | 12.341 | 8.841 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 17.095 | 9.109 | 21.458 | 24.933 | 38.410 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 91.7% | ▼-3.7% | ▼-5.5% |
| Ebit Margin | 34.0% | ▼-9.1% | ▼-7.3% |
| Ebitda Margin | 35.9% | ▼-9.1% | ▼-7.6% |
| Operating Profit Margin | 33.6% | ▲2.5% | ▼-1.5% |
| Pretax Profit Margin | 32.4% | ▼-10.2% | ▼-8.3% |
| Continuous Operations Profit Margin | 25.9% | ▼-10.5% | ▼-6.4% |
| Net Profit Margin | 25.9% | ▼-10.5% | ▼-6.4% |
| Bottom Line Profit Margin | 25.9% | ▼-10.5% | ▼-6.4% |
| Current Ratio | 2.022 | ▼-3.226 | ▼-8.096 |
| Quick Ratio | 2.009 | ▼-3.227 | ▼-8.099 |
| Solvency Ratio | 0.148 | ▼-0.758 | ▼-0.986 |
| Cash Ratio | 1.202 | ▼-0.655 | ▼-2.835 |
| Price To Earnings Ratio | 19.910 | ▲7.523 | ▼-11.564 |
| Price To Earnings Growth Ratio | -0.228 | ▼-0.376 | ▲0.317 |
| Forward Price To Earnings Growth Ratio | -0.228 | ▼-0.376 | ▲0.317 |
| Price To Earnings Diluted Ratio | 20.039 | ▲7.652 | ▼-11.631 |
| Price To Earnings Diluted Growth Ratio | -0.229 | ▼-0.377 | ▲0.331 |
| Price To Book Ratio | 3.281 | ▲0.634 | ▼-1.736 |
| Price To Sales Ratio | 5.142 | ▲0.628 | ▼-5.182 |
| Price To Free Cash Flow Ratio | 16.647 | ▲3.836 | ▼-21.116 |
| Price To Operating Cash Flow Ratio | 16.128 | ▲3.625 | ▼-18.460 |
| Debt To Assets Ratio | 0.422 | ▲0.400 | ▲0.322 |
| Debt To Equity Ratio | 0.930 | ▲0.902 | ▲0.725 |
| Debt To Capital Ratio | 0.482 | ▲0.455 | ▲0.367 |
| Long Term Debt To Capital Ratio | 0.462 | ▲0.462 | ▲0.369 |
| Financial Leverage Ratio | 2.202 | ▲0.953 | ▲0.846 |
| Working Capital Turnover Ratio | 0.310 | ▼-0.499 | ▼-0.238 |
| Operating Cash Flow Ratio | 0.834 | ▼-0.630 | ▼-0.933 |
| Operating Cash Flow Sales Ratio | 0.319 | ▼-0.042 | ▼-0.014 |
| Free Cash Flow Operating Cash Flow Ratio | 0.969 | ▼-0.007 | ▲0.029 |
| Debt Service Coverage Ratio | 3.281 | ▼-66.528 | ▼-151.152 |
| Interest Coverage Ratio | 20.492 | ▼-35.367 | ▼-139.310 |
| Short Term Operating Cash Flow Coverage Ratio | 4.348 | ▲4.348 | ▲3.478 |
| Operating Cash Flow Coverage Ratio | 0.219 | ▼-7.333 | ▼-5.611 |
| Capital Expenditure Coverage Ratio | 32.054 | ▼-9.502 | ▲9.170 |
| Dividend Paid And Capex Coverage Ratio | 32.054 | ▼-9.502 | ▲9.170 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 17.095 | ▲7.986 | ▼-5.106 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $19.14B | $97.16B | $141.71B | $192.46B | $169.12B | |
| Enterprise value | $22.86B | $88.33B | $127.61B | $183.16B | $160.59B | |
| EV / Sales | 6.14x | 4.10x | 7.75x | 12.63x | 19.08x | |
| EV / Op. cash flow | 19.26x | 11.37x | 17.29x | 46.82x | 72.08x | |
| EV / Free cash flow | 19.88x | 11.65x | 18.22x | 50.95x | 81.27x | |
| EV / EBITDA | 17.09x | 9.11x | 21.46x | 24.93x | 38.41x | |
| Net debt / EBITDA | 2.78x | -0.91x | -2.37x | -1.26x | -2.04x | |
| Current ratio | 2.02x | 5.25x | 13.34x | 15.48x | 14.50x | |
| Income quality | 1.23x | 0.99x | 1.31x | 0.56x | 0.56x | |
| Graham number | $181 | $1K | $844 | $885 | $588 | |
| Graham net-net | -$7 | $26 | $43 | $36 | $30 | |
| Tax burden | 80.0% | 85.6% | 77.2% | 78.5% | 75.5% | |
| Interest burden | 95.2% | 98.7% | 98.8% | 99.7% | 99.7% | |
| Working capital | $1.45B | $22.55B | $30.66B | $26.39B | $21.17B | |
| Invested capital | $11.19B | $37.69B | $32.40B | $27.86B | $22.40B | |
| Return on assets | 7.5% | 17.1% | 12.3% | 18.1% | 12.0% | |
| Operating ROA | 4.3% | 16.5% | 16.3% | 22.9% | 12.9% | |
| Return on tangible assets | 28.5% | 25.4% | 12.4% | 18.2% | 12.1% | |
| Return on equity | 16.5% | 21.4% | 13.8% | 20.0% | 13.3% | |
| Return on invested capital | 8.5% | 14.1% | 12.5% | 17.3% | 9.6% | |
| Return on capital employed | 11.0% | 16.5% | 16.2% | 22.1% | 12.8% | |
| Earnings yield | 5.0% | 8.1% | 3.1% | 2.8% | 1.7% | |
| Free cash flow yield | 6.0% | 7.8% | 4.9% | 1.9% | 1.2% | |
| Capex / Op. cash flow | 3.1% | 2.4% | 5.1% | 8.1% | 11.3% | |
| Capex / Depreciation | 52.1% | 45.3% | 127.5% | 87.6% | 101.6% | |
| Capex / Sales | 1.0% | 0.9% | 2.3% | 2.2% | 3.0% | |
| SG&A / Sales | 16.2% | 17.6% | 20.0% | 18.4% | 15.2% | |
| R&D / Sales | 41.9% | 45.3% | 46.3% | 38.3% | 49.7% | |
| Stock comp / Sales | 0.0% | 3.3% | 3.6% | 3.0% | 3.7% | |
| Intangibles / Total assets | 73.6% | 32.5% | 0.3% | 0.5% | 1.0% | |
| Days sales outstanding | 113d | 113d | 110d | 144d | 146d | |
| Days payables outstanding | 1259d | 0d | 0d | 0d | 0d | |
| Operating cycle | 134d | 136d | 202d | 144d | 146d | |
| Cash conversion cycle | -1125d | 136d | 202d | 144d | 146d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-06 Genmab Shares Climb After Positive Study Results for Blood-Cancer Drug The Danish company said the Epkinly drug helped extend the time patients with a common type of lymphoma lived.
- 2026-10-05 Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell [url="]Genmab A/S[/url](Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced today positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed tr
- 2026-10-05 AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients wi
- 2026-10-05 AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (PFS) in frontline diagnosed diffuse large B-cell lymphoma (DLBCL) patients Based on the topline results, Genmab and AbbVie will engage global regulatory authorities NORTH CHICAGO, Ill. and COPENHAGEN, Denmark, Oct. 5, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) today announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with standard of care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP), compared to R-CHOP alone, in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of 2 to 5.
- 2026-10-05 Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Company Announcement COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; October 5, 2026 EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (PFS) in frontline diagnosed diffuse large B-cell lymphoma (DLBCL) patients Based on the topline results, Genmab and AbbVie will engage global regulatory authorities Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced today positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with standard of care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP), compared to R-CHOP alone, in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of 2 to 5.
- 2026-10-03 Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer [url="]Genmab A/S[/url] (Nasdaq: GMAB) today announced results from Part C of the Phase 1/2 RAINFOLâ¢-01 trial evaluating rinatabart sesutecan (Rina-S), an inv
- 2026-10-03 Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer Media Release COPENHAGEN, Denmark; October 3, 2026 Treatment with Rina-S ® 120 mg/m² every three weeks demonstrated a clinically meaningful objective response rate (ORR) and durable median duration of response (mDOR) in patients with platinum-resistant ovarian cancer (PROC) Antitumor activity was observed regardless of folate receptor alpha (FRα) expression levels, including low FRα expression and non-expressors Genmab A/S (Nasdaq: GMAB) today announced results from Part C of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), demonstrated that among 109 treated patients with platinum-resistant ovarian cancer (PROC), Rina-S achieved a confirmed objective response rate (ORR) of 45.9% (95% CI: 36.3–55.7), including five complete responses (CRs) and a median duration of response (mDOR) of 12.1 months (95% CI: 6.5–15.4), with 51% of responders remaining in response at one year. The findings were presented today in a Late-Breaking Oral Session at the International Gynecologic Cancer Society (IGCS) Congress 2026, held in Montreal, Canada.
- 2026-10-03 Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced results from Part C of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), demonstrated that among 109 treated patients with platinum-resistant ovarian cancer (PROC), Rina-S achieved a confirmed objective response rate (ORR) of 45.9% (95% CI: 36.3–55.7), including five compl.
- 2026-10-02 Major Shareholder Announcement Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; October 2, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Darwin Global Management Limited (“Darwin”) has informed us that, as of September 28, 2026, Darwin through shares and ADRs held by certain investment funds and portfolios for which Darwin acts as investment manager, controls the voting rights attached to 3,188,361 shares in Genmab A/S, corresponding to 5.11% of the voting rights in Genmab A/S. About Genmab Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines.
- 2026-09-26 Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4 Genmab A/S NASDAQ: GMAB expects a pivotal fourth quarter, with Phase III readouts planned for three late-stage oncology programs that the company views as potential first-in-class opportunities, according to Andrew Carlsen, the company''s vice president and head of investor relations.